Table 2.

Comparison among plasma concentration and K_p ratios in wild-type and Mrp4^-/- mice received a continuous subcutaneous infusion

	Dose (nmol/h)	Animals	n	Cp (μM)	Kp,brain	fold difference (KO/WT)	Kp,CSF	fold difference (KO/WT)
cefazolin	700	WT	4	35 ± 4	0.034 ± 0.009	<1.0	NT
		KO	4	29 ± 0	0.015 ± 0.001
cefmetazole	680	WT	4	8.7 ± 1.7	0.016 ± 0.012	<1.0	NT
		KO	4	8.7 ± 0.8	0.008 ± 0.002
ciprofloxacin	97	WT	4	0.18 ± 0.04	0.061 ± 0.016	1.6	NT
		KO	4	0.14 ± 0.02	0.096 ± 0.019
cyclophosphamide	1500	WT	3	0.0073 ± 0.0015	0.73 ± 0.12	2.1*	NT
		KO	3	0.0046 ± 0.0004	1.5 ± 0.1
furosemide	120	WT	4	7.6 ± 1.5	0.010 ± 0.002	1.0	NT
		KO	4	7.9 ± 0.9	0.011 ± 0.001
hydrochlorothiazide	1100	WT	4	10 ± 1	0.11 ± 0.01	1.2	NT
		KO	4	14 ± 3	0.13 ± 0.03
methotrexate	180	WT	4	3.3 ± 0.2	0.022 ± 0.003	1.9 **	0.018±0.003	1.5
		KO	4	3.3 ± 0.2	0.042 ± 0.003		0.026±0.003
pitavastatin	95	WT	4	0.93 ± 0.10	0.031 ± 0.007	<1.0	NT
		KO	4	1.0 ± 0.3	0.027 ± 0.010
pravastatin	720	WT	4	1.4 ± 0.1	0.036 ± 0.003	1.2	NT
		KO	4	2.0 ± 0.3	0.042 ± 0.018
raltitrexed	350	WT	4	7.9 ± 0.9	0.016 ± 0.002	2.5 **	0.013±0.002	1.8**
		KO	4	9.2 ± 1.1	0.041 ± 0.003		0.024±0.002

^*P < 0.05 and

^**P < 0.01

WT, wild-type mice; KO, Mrp4^-/- mice; NT, not tested